Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study.
Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients.
Taylor
S A
SA
University of Kansas Medical Center.
Fleming
T
T
Von Hoff
D D
DD
McCracken
J D
JD
Bukowski
R M
RM
Talley
R W
RW
Natale
R B
RB
Guy
J T
JT
Samlowski
W E
WE
Costanzi
J H
JH
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
D008942:Mitoxantrone